Detection of Colorectal Disease by Stool Defensin Assay: An Exploratory Study  Hongzhi Zou, Jonathan J. Harrington, Aravind Sugumar, Kristie K. Klatt, Thomas C. Smyrk, David A. Ahlquist  Clinical Gastroenterology and Hepatology  Volume 5, Issue 7, Pages 865-868 (July 2007) DOI: 10.1016/j.cgh.2007.03.013 Copyright © 2007 AGA Institute Terms and Conditions

Figure 1 The mRNA expression levels of HNP1-3 quantified by real-time reverse transcription–PCR in colon cancer cell lines (HT29, SW480, SNUC4, SW620, HCT15, and WIDR), CRC tissues, normal (NL) colorectal epithelia, white blood cells, and neutrophils. HNP1-3 levels in CRC and NL were only plotted with medians here. Clinical Gastroenterology and Hepatology 2007 5, 865-868DOI: (10.1016/j.cgh.2007.03.013) Copyright © 2007 AGA Institute Terms and Conditions

Figure 2 The protein concentration of HNP1-3 quantified by ELISA in stools from normal individuals, patients with CRC, colorectal adenoma, upper gastrointestinal cancers (UGC), and IBD. Each circle represents a stool sample. The solid horizontal bar indicates the mean of HNP1-3 concentration within a group of subjects. Clinical Gastroenterology and Hepatology 2007 5, 865-868DOI: (10.1016/j.cgh.2007.03.013) Copyright © 2007 AGA Institute Terms and Conditions

Figure 3 Correlation of HNP1-3 protein with lactoferrin, a known inflammatory marker, in stool samples. Correlation was significant (R2 = 0.70, P < .001). Clinical Gastroenterology and Hepatology 2007 5, 865-868DOI: (10.1016/j.cgh.2007.03.013) Copyright © 2007 AGA Institute Terms and Conditions